Peptide Stack

SS-31 + MOTS-c

Elamipretide MOTS-c · mitochondrial stack · SS-31/MOTS-c

Named mitochondrial blend of SS-31 (elamipretide) plus MOTS-c. Elamipretide is FDA accelerated-approved as Forzinity™ for Barth syndrome ≥30 kg (Sep 2025) — that product is not this stack. MOTS-c remains research-only. Gray-market combo vials are not a Barth protocol and are not an approved combination.

Not FDA-approved — research chemical
Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Low2 peer-reviewed citations
Typical research dose
Research vials vary; not the Forzinity Barth dose. MOTS-c often 5-10 mg/week in community protocols
Frequency
SS-31 often daily in trials · MOTS-c several times weekly
Half-life
~4 h (elamipretide) / estimated hours (MOTS-c)
Common vials
10 mg
CAS
N/A (blend)
Dose it
10 mg + 2 mL BAC water → 5 mg/mL · 5000 mcg ≈ 100 units (U-100)
Open in calculator

Mechanism of Action

SS-31 (elamipretide) binds cardiolipin on the inner mitochondrial membrane. MOTS-c is a 16-aa peptide encoded in the mitochondrial 12S rRNA region, studied as an AMPK-linked metabolic signal.

Elamipretide received FDA accelerated approval in September 2025 as Forzinity™ for Barth syndrome in patients ≥30 kg. That is a single-agent, single-indication product. This stack is a research-chem pairing. Do not copy Forzinity dosing onto a blended vial.

Source: SS-31 PMID: 26857943; MOTS-c PMID: 25738459; Forzinity FDA accelerated approval Sep 2025

Not Forzinity

Forzinity is elamipretide for Barth syndrome. MOTS-c is not on that label. A gray-market combo is not mitochondrial-disease care.

Dosing Protocol

Typical DoseResearch vials vary; not the Forzinity Barth dose. MOTS-c often 5-10 mg/week in community protocols
FrequencySS-31 often daily in trials · MOTS-c several times weekly
Half-Life~4 h (elamipretide) / hours-class (MOTS-c, estimated)
Common Vial Sizes10 mg

Dosing Protocols

Approved elamipretide

Dose
Forzinity PI only
Frequency
Per label
Note: Barth syndrome ≥30 kg. Not this stack.

Research blend

Dose
Vendor-defined
Frequency
Vendor-defined
Note: Calculator is vial math. Not a protocol.

Administration

Route
Subcutaneous (research vials)
Timing
Not established for the combo.
Fasting Required?
No — food timing not critical

Expected Timeline

Label (Forzinity)
Barth muscle-strength intermediate endpoint — not a biohacking timeline.

Who Is It For?

Barth syndrome

High

That is Forzinity (elamipretide alone), prescribed. Not this page.

Research stack SKU

Low

Two mitochondrial-adjacent peptides in one bottle. No combo approval.

Reconstitution Example

Vial
10 mg
Diluent
2 mL
Concentration
5 mg/mL
Per Unit (100u syringe)
50 mcg
Dose of 5000 mcg = 100 units on a 100-unit insulin syringe
🧮 Calculate Your Exact SS-31 + MOTS-c Dose →

Safety & Considerations

Elamipretide is a prescription drug for a rare disease. MOTS-c has no human approval. Mixing them does not create a sports-performance protocol. Injection-site reactions; unknown combo safety.

Regulatory & Legal Status

FDA Status (US)
Research Only

SS-31 is Forzinity™ for Barth syndrome alone. MOTS-c is research-only. The blend is not approved

WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

SS-31 + MOTS-c vs. SS-31 (elamipretide)

AttributeSS-31 + MOTS-cSS-31 (elamipretide)
IdentityElamipretide + MOTS-c blendElamipretide alone
FDANot an approved combinationForzinity™ accelerated approval (Barth, Sep 2025)
JobVendor mitochondrial stackLabeled Barth product or research vial

Verdict: The stack is not Forzinity. Elamipretide’s approval is a single-agent, single-indication story.

Dosing Quick Reference

SS-31 + MOTS-c— Dosing Guide
Dose Range
Research vials vary; not the Forzinity Barth dose. MOTS-c often 5-10 mg/week in community protocols
Half-Life
~4 h (elamipretide) / hours-class (MOTS-c, estimated)
Frequency
SS-31 often daily in trials · MOTS-c several times weekly
Route
Subcutaneous
10 mg vial
💧 2 mL BAC water📐 5 mg/mL💉 50 mcg/unit (100u syringe)
Peptide Stackcalcmypeptide.com

Frequently Asked Questions

Is SS-31 FDA-approved?▼
Elamipretide is Forzinity, accelerated approval Sep 2025 for Barth syndrome ≥30 kg. Research vials and this blend are not that product.
Can I use Forzinity doses in this calculator?▼
No. Use the PI. This leaf is identity for a vendor stack plus reconstitution arithmetic.

References

  1. Szeto / Stealth lineage “Elamipretide / SS-31 mitochondrial membrane work.” Mitochondrial literature (2016). PMID: 26857943
  2. Lee C et al. “MOTS-c is a mitochondrial-encoded peptide.” Cell Metabolism (2015). PMID: 25738459

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code

← Back to Peptide Library